Clone:
REAL218
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC, MICS, IF, IHC
Alternative names:
ENG, END, HHT1, ORW1, Endoglin

Extended validation for CD105 Antibody, anti-human,
REAlease
®

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD105 (REAL218). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD105 Antibody, anti-human,
REAlease
®

Overview

Clone REAL218 is an antibody fragment derived from the full CD105 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL218 recognizes the CD105 antigen, also known as endoglin, which serves as a receptor for the growth and differentiation factors TGF-β1 and TGF-β3. An epitope of CD105 is recognized by the SH-2 antibody, which was raised against human mesenchymal stromal cells (MSC) that show mesodermal differentiation capacity. Therefore, it can be used for studies on mesengenesis. CD105 is also expressed on mature endothelial cells and on some leukemic cells of B lymphoid and myeloid origin.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

ENG, END, HHT1, ORW1, Endoglin

Detailed product information

Technical specifications

CloneREAL218
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD105
Alternative names of antigenENG, END, HHT1, ORW1, Endoglin
Distribution of antigenendothelial cells, B cells, myeloid cells
RRIDAB_2751248, AB_2783903, AB_2819672, AB_2819671, AB_2751254

Resources for CD105 Antibody, anti-human,
REAlease
®

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD105 Antibody, anti-human,
REAlease
®

Publications

  1. Bellón, T. et al. (1993) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23(9): 2340-2345
  2. Barry, F. P. et al. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265: 134-139
  3. Majumdar, M. K. et al. (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J. Cell. Physiol. 185: 98-106

Related products for
CD105 Antibody, anti-human,
REAlease
®

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?